Blockbuster performance: Regeneron, Sanofi add stellar PhIII dupilumab data on display at EADV
After a steady drumbeat of praise from Regeneron and its partners at Sanofi, investigators today backed up their unblushing optimism over their late-stage drug prospect dupilumab with a batch of stellar late-stage trial data for atopic dermatitis, adding to the positive profile already sketched out.
The scientists turned up at the European Academy of Dermatology and Venereology in Vienna to review the data from SOLO1 and SOLO2. And it was worth the wait for a drug they plan to market as Dupixent as they look to start racking up revenue against the multibillion-dollar peak sales estimates that have hovered around this drug.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.